Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Southern Brazil

Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Southern Brazil

Background: It is believed that Human Papillomavirus (HPV) and Human Immunodeficiency Virus coinfection contributes to increase the risk for cervical intraepithelial injuries. Several factors may contribute to cervical cancer (CC) development, including genetic variants such as TP53 and MDM2 gene po...

Full description

Bibliographic Details
Main Authors:	Ludmila Gonçalves Entiauspe, Fabiana Kömmling Seixas, Emily Montosa Nunes, Fernanda Martins Rodrigues, Odir A. Dellagostin, Tiago Collares, Mariângela Freitas da Silveira
Format:	Article
Language:	English
Published:	Elsevier 2014-11-01
Series:	Brazilian Journal of Infectious Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S1413867014001706

Similar Items

Evidence for an epistatic effect between TP53 R72P and MDM2 T309G SNPs in HIV infection: a cross-sectional study in women from South Brazil.
by: Fernando Pires Hartwig, et al.
Published: (2014-01-01)

Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
by: Shenying Fang, et al.
Published: (2010-05-01)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
by: Dmitriy Sonkin
Published: (2015-10-01)

Auxotrophic <i>Mycobacterium bovis</i> BCG: Updates and Perspectives
by: Odir Antônio Dellagostin, et al.
Published: (2022-05-01)

Regulators of Oncogenic Mutant TP53 Gain of Function
by: Satomi Yamamoto, et al.
Published: (2018-12-01)

TP53 GENE MUTATIONS – FROM GUARDIAN OF THE GENOME TO ONCOGENE
by: Petar Babović, et al.
Published: (2010-03-01)

<it>TP</it>53 and <it>MDM2 </it>gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
by: Buonaguro Franco M, et al.
Published: (2011-08-01)

Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
by: Yasuki Hori, et al.
Published: (2015-01-01)

Rational design of diagnostic and vaccination strategies for tuberculosis
by: Sibele Borsuk, et al.
Published: (2012-01-01)

Rational design of diagnostic and vaccination strategies for tuberculosis
by: Sibele Borsuk, et al.

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
by: Tanya Jindal, et al.
Published: (2023-04-01)

Genetic polymorphisms of <it>MDM2 </it>and <it>TP53 </it>genes are associated with risk of nasopharyngeal carcinoma in a Chinese population
by: Xiao Mang, et al.
Published: (2010-04-01)

Correction: impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.
by: PLOS ONE Staff
Published: (2015-01-01)

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
by: Ranjan Chrisanthar, et al.
Published: (2011-04-01)

The <i>TP53</i> Codon 72 Arginine Polymorphism Is Found with Increased <i>TP53</i> Somatic Mutations in HPV(−) and in an Increased Percentage among HPV(+) Norwegian HNSCC Patients
by: Svein Erik Moe, et al.
Published: (2023-06-01)

Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma
by: Venkatesh Kancherla, et al.
Published: (2018-02-01)

LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53
by: Shaoxian Liu, et al.
Published: (2018-07-01)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
by: Melania Tesio
Published: (2023-02-01)

The HPV-TP53-MALAT1 Axis: Unravelling interactions in cervical cancer development.
by: Saba Iordanishvili, et al.
Published: (2023-01-01)

The HPV-TP53-MALAT1 Axis: Unravelling interactions in cervical cancer development
by: Saba Iordanishvili, et al.
Published: (2023-01-01)

<i>TP53</i>-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer
by: Lennart Versemann, et al.
Published: (2022-07-01)

Transglutaminase 2 contributes to a TP53-induced autophagy program to prevent oncogenic transformation
by: Shi Yun Yeo, et al.
Published: (2016-03-01)

Evaluation of HER2, MDM2, MYC, MET and TP53 gene copy number alterations in gastric cancer patients
by: Fatemeh Nevisi, et al.
Published: (2020-01-01)

The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk.
by: Chuanbo Fan, et al.
Published: (2014-01-01)

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction.
by: Kelly M Thayer, et al.
Published: (2016-01-01)

Haplotype structure and selection of the MDM2 oncogene in humans.
by: Atwal, G, et al.
Published: (2007)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
by: Zuzana Mrkvová, et al.
Published: (2019-06-01)

TP53 promoter methylation in EBV and HPV associated oropharyngeal carcinoma – a pilot study
by: Jarzynski Adrian, et al.
Published: (2017-09-01)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
by: Haiwei Wang, et al.
Published: (2022-06-01)

TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
by: Cheng Xu, et al.
Published: (2021-11-01)

TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
by: Qiliu Peng, et al.
Published: (2013-01-01)

MDM2 inhibitors: Targeting p53-MDM2 interaction to anti-cancer
by: Zhang Xulin
Published: (2021-01-01)

Detection of P53 and Mdm2 in vitiligo
by: Viroj Wiwanitkit
Published: (2013-01-01)

Evolution of the p53-MDM2 pathway
by: Emma Åberg, et al.
Published: (2017-08-01)

Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner
by: Ying Li, et al.
Published: (2022-09-01)

Pathogenic TP53 mutations influence chemotherapy response and survival rate of HPV-negative oral carcinomas
by: Jović Saša, et al.
Published: (2022-01-01)

Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
by: Vera V. Grinkevich, et al.
Published: (2022-06-01)

The cell cycle regulatory gene polymorphisms TP53 (rs1042522) and MDM2 (rs2279744) in lung cancer: a meta-analysis
by: O. Bulgakova, et al.
Published: (2020-12-01)

Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review
by: Meijia Yu, et al.
Published: (2022-08-01)

PFKFB4 Drives the Oncogenicity in TP53-Mutated Hepatocellular Carcinoma in a Phosphatase-Dependent MannerSummary
by: Charles Shing Kam, et al.
Published: (2023-01-01)